LLY
1,008.98
-0.15%↓
JNJ
201.79
-0.2%↓
ABBV
226.23
-1.07%↓
UNH
330.51
-0.85%↓
AZN
90.18
+0.23%↑
LLY
1,008.98
-0.15%↓
JNJ
201.79
-0.2%↓
ABBV
226.23
-1.07%↓
UNH
330.51
-0.85%↓
AZN
90.18
+0.23%↑
LLY
1,008.98
-0.15%↓
JNJ
201.79
-0.2%↓
ABBV
226.23
-1.07%↓
UNH
330.51
-0.85%↓
AZN
90.18
+0.23%↑
LLY
1,008.98
-0.15%↓
JNJ
201.79
-0.2%↓
ABBV
226.23
-1.07%↓
UNH
330.51
-0.85%↓
AZN
90.18
+0.23%↑
LLY
1,008.98
-0.15%↓
JNJ
201.79
-0.2%↓
ABBV
226.23
-1.07%↓
UNH
330.51
-0.85%↓
AZN
90.18
+0.23%↑
24h
Current
Min
10.28
Max
10.4
Income | -73M -99M |
|---|---|
Sales | 9.1M 11M |
Profit margin | -876.339 |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +49.61% upside |
Market Cap | 377M |
|---|---|
Previous open | 12.61 |
Previous close | 10.34 |
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
8 maj 2025, 19:14 UTC
Verastem Ovarian-Cancer Drug Combination Gets FDA Approval -- Update
DJ
Read
31 gru 2024, 19:15 UTC
Verastem Shares Soar on FDA Priority Review of Cancer Treatment
DJ
Read
Price change
By TipRanks
12 Months Forecast
Average 15.5 USD 49.61%
High 20 USD
Low 14 USD
Based on 7 Wall Street analysts offering 12 month price targets forVerastem Inc - Dist in the last 3 months.
By TipRanks
Strong Buy
7 ratings
7
Buy
0
Hold
0
Sell
Based on 7 analysts giving stock ratings to Verastem Inc - Dist in the past 3 months.
Selling and administration expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$